121P - Survival following treatment of non-small cell lung cancer (NSCLC) using continuous hyperfractionated accelerated radiotherapy (CHART): A single-ce...

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Surgical Oncology
Non-Small Cell Lung Cancer
Therapy
Radiation Oncology
Presenter Gareth Ayre
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors G. Ayre, G. Casswell, C. Comins, S. Falk
  • Oncology, University Hospitals Bristol NHS Trust Bristol Haematology and Oncology Centre, BS2 8ED - Bristol/GB

Abstract

Background

CHART is the preferred schedule of radical radiotherapy for all patients of good performance status in Bristol. In this single-centre retrospective analysis, we report survival data for all patients treated from 2004 to 2009.

Methods

Patients treated with CHART between January 2004 and December 2009 were identified to allow a minimum of 5 years of follow-up. We carried out a retrospective analysis of data to assess patient demographics, tumor characteristics, treatment details and survival.

Results

A total of 150 patients treated in this period were identified and records were available for analysis in 149 of these patients. 137 patients (92%) had a WHO performance status of 0 or 1. PET scans were performed in 59 (40%) of cases and 58 (39%) of patients underwent induction chemotherapy prior to CHART. The number of patients with stage I, II or III/IV disease was 35 (25%), 16 (11%) and 89 (63%) respectively. At the time of data analysis, 109 patients (73%) had documented disease progression and 134 (90%) had died. Median survival from the start of radiotherapy was 20.9 months. 2, 3 and 5-year overall survival were 41%, 26% and 17% which compare well with previously published data. On univariate analysis, stage, anaemia (Hb 

Conclusions

Outcomes following CHART in routine practice compare favourably with previously published trial data. PET-CT staging did not significantly improve survival in this cohort. Anaemia is a significant predictor of survival and further investigation of the benefits of an aggressive transfusion strategy is warranted. This is of particular significance in patients receiving induction chemotherapy.

Clinical trial identification

Legal entity responsible for the study

University Hospitals Bristol NHS Foundation Trust

Funding

University Hospitals Bristol NHS Foundation Trust

Disclosure

All authors have declared no conflicts of interest.